Peripheral arterial disease (PAD) is a common condition characterized by reduced blood flow to the limbs, causing pain and cramping during physical activity. In addition to the physical symptoms, patients with PAD are at a higher risk of cardiovascular events, including myocardial infarction, stroke, cardiovascular related death, and chronic limb threatening ischemia. Statin therapy has been shown to improve walking parameters in patients with PAD and claudication, and a study by Clavijo et al. in this issue of Cardiovascular Revascularization Medicine suggests that adding evolocumab to statin therapy can further enhance walking performance in these patients.